Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$29.03M

FY 2025 · Annual

Investing Cash Flow

-$598,767.00

FY 2025 · Annual

Financing Cash Flow

$77.33M

FY 2025 · Annual

+68.9% YoY

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Net Income(18.18M)(18.99M)(21.81M)(25.74M)(39.22M)
Depreciation & Amortization88.17K147.89K117.1K171.72K241.68K
Deferred Income Tax00000
Stock-Based Compensation01.43M1.06M3.22M0
Change in Working Capital(167.16K)1.51M4.03M(6.76M)(725.6K)
Accounts Receivables150.92K230.48K(78.09K)(101.39K)(438.64K)
Inventory00000
Accounts Payables01.32M435.12K(714.88K)2.4M
Other Working Capital(318.07K)(39.96K)3.67M(5.95M)(2.69M)
Other Non-Cash Items6.68M1.5M977.18K(880.5K)10.68M
Operating Cash Flow(11.58M)(14.4M)(15.62M)(29.99M)(29.03M)
Capital Expenditures(341.28K)(235.55K)(55.25K)(104.23K)(598.77K)
Acquisitions (Net)00000
Purchases of Investments(7.12M)(3.27M)000
Sales of Investments013.34M000
Other Investing Activities(3.97M)242029.07K0
Investing Cash Flow(11.42M)9.83M(55.25K)(75.16K)(598.77K)
Debt Repayment9.62M(142.27K)(59.81K)(9.14M)0
Common Stock Issued29.91M10.64M11.96M54.56M77.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(69.33K)306.77K3.97M363.06K0
Financing Cash Flow39.46M10.8M15.87M45.78M77.33M
Effect of Forex Changes(63.69K)(507.4K)618.45K(1.96M)(403.1K)
Net Change in Cash16.4M5.73M811.93K13.76M47.3M
Free Cash Flow(11.92M)(14.63M)(15.68M)(30.1M)(29.63M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$39.2M
+ D&A$241.7K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$725.6K
+ Other Non-Cash$10.7M
= Operating Cash Flow-$29.0M
- Capex-$598.8K
= Free Cash Flow-$29.6M

Analysis

FY2025 free cash flow is -$29.6M. FCF conversion is 75.5% of net income. Operating cash flow was -$29.0M, with capex of -$598.8K. The largest bridge item is Other Non-Cash at $10.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-8S-8 filingNov 12, 2026
6-K6-K filingNov 10, 2026
6-K6-K filingNov 10, 2026
6-K6-K filingNov 10, 2026
6-K6-K filingNov 10, 2026

Does EPRX generate free cash flow?

Eupraxia Pharmaceuticals Inc. (EPRX) generated -$29.63M of free cash flow in fiscal 2025.

How much operating cash flow does EPRX produce?

Operating cash flow was -$29.03M, before capital expenditures of $598,771.00.